According to Cleveland.com, Athersys, Inc has successfully completed treating its first clinical trial patient at the Cleveland Clinic. They're using stem cell therapy to determine the maximum dosage of Multistem, a medicine that is used after a heart attack.
B.J. Lehmann, president and chief operating officer, at Athersys, had this to say about the success:
"We are excited about the potential of MultiStem to provide benefit in multiple diseases and conditions, and we look forward to providing additional information about this Phase I clinical trial and other studies as we move our programs ahead."
Showing posts with label Heart attack. Show all posts
Showing posts with label Heart attack. Show all posts
Tuesday, October 14, 2008
Thursday, October 9, 2008
AcelleRX Therapeutics Inc will finance clinical trial
AcelleRX Therapeutics Inc., a Cleveland, Ohio, based company, will finance it's first clinical trial on cardiovascular stem cell therapy. It received a $6.9 million investment. The company's main product is Stromal Derived Factor-1, which is given to patients immediately following a heart attack or heart failure. Read more here.
Subscribe to:
Posts (Atom)
